Acars	acylcarnitines;
CCS	collisional cross section;
CE	collision energy;
Cers	ceramides;
CMP-Neu5Ac	Cytidine-5-monophospho-N-acetylneuraminic acid;
FA	fatty acid;
GlcCer	Glucosylceramide;
GNEM	GNE myopathy;
GSLs	glycosphingolipids;
HIBM	hereditary inclusion body myopathy;
LPCs	lysophosphocholines;
LPCATs	lysophosphatidylcholine acyltransferases;
LPE	lysophosphatidylethanolamine;
LPG	lysophosphatidylglycerol;
LPLAT	lysophospholipid acyltransferase;
ManNac-kinase	N-acetylmannosamine kinase;
MCP1	monocyte chemoattractant protein-1;
MCVs	missing cryptic variants;
MDH	malate dehydrogenase;
MSTFA	N-methyl-N-(trimethylsilyl) trifluoroacetamide;
MVA	multivariate statistical analysis;
NeuAc	N-acetylneuraminic acid;
NIA	negative ionization analysis;
OPLS-DA	orthogonal partial least squares analysis;
PA	phosphatidic acid;
PCs	phosphocholines;
PCA	principal component analysis;
PE	phosphatidylethanolamine;
PG	phosphatidylglycerol;
PKB	protein kinase B;
PIA	positive ionization analysis;
PLA2	phospholipase A2;
PLS-DA	partial least squares analysis;
QC	quality control;
SMs	sphingomyelins;
SMases	sphingomyelinases;
TCA	Krebs cycle;
TGs	triacylglycerols;
VUSs	variants of unknown significance;
UDP-GlcNAc	UDP-N-acetylglucosamine.